The Claim
Oxidized eicosapentaenoic acid (EPA) exhibits greater potency than native EPA in activating PPARα in endothelial cells, with a half-maximal effective concentration of 10 µM for oxidized EPA compared to 30 µM for fenofibric acid.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Oxidized EPA activates the PPARα protein in endothelial cells more strongly than unmodified EPA, requiring a lower concentration to achieve half of its maximum effect compared to the synthetic drug fenofibric acid.
See the scientific wording
Oxidized eicosapentaenoic acid (EPA) is more potent than native EPA in activating PPARα in endothelial cells, with an estimated half-maximal activity at 10 µM compared to 30 µM for fenofibric acid, a synthetic PPARα agonist.
When EPA is oxidized, it enters endothelial cells and binds tightly to PPARα, turning on this receptor more strongly than regular EPA. Activated PPARα blocks a key inflammation signal called NF-κB, which stops the cell from making proteins that attract white blood cells. This reduces the stickiness of blood vessel walls and prevents white blood cells from attaching.
What the research says
1 studyThe study quantified PPARα activation using a luciferase reporter assay and calculated EC50 values, showing oxidized EPA had higher potency than both native EPA and fenofibric acid. This provides precise, measurable evidence of relative activation strength.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.